Trofosfamide
Jump to navigation
Jump to search
| Clinical data | |
|---|---|
| Trade names | Ixoten |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | By mouth (film-coated tablets) |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| E number | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C9H18Cl3N2O2P |
| Molar mass | 323.58 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Trofosfamide (INN) is a nitrogen mustard alkylating agent. It is sometimes abbreviated "TRO".[1] It has been used in trials to study its effects on ependymoma, medulloblastoma, sarcoma, soft tissue,[clarification needed] supratentorial PNET, and recurrent brain tumors.[2]